Hospitalization for Lower Respiratory Tract Disease in Preterm Infants: Effects of Prophylaxis with Palivizumab

REFERENCES

• Bosis S, Esposito S, Niesters HG, Zuccotti GV, Marseglia G, Lanari M, et al. Role of respiratory pathogens in infants hospitalized for a first episode of wheezing and their impact on recurrences. Clin Microbiol Infect 2008;14 (7): 677–684.
   PubMed Web of Science ®Google Scholar
• Corsello G, Di Carlo P, Salsa L, Gabriele B, Meli L, Bruno S, Titone L. Respiratory syncytial virus infection in a Sicilian pediatric population: risk factors, epidemiology, and severity. Allergy Asthma Proc 2008; 29 (2): 205–210.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Terrosi C, Martorelli B, Valentini M, Bernini L, Cellesi C, Cusi MG. Epidemiological and clinical study of viral respiratory tract infections in children from Italy. J Med Virol 2009; 81 (4) :750–756.
   PubMed Web of Science ®Google Scholar
• Welliver R. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003; 143 (Suppl.5): S112-S117.
   Google Scholar
• Carbonell-Estrany X, Figueras-Aloy J, Law B. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent find-ings. Pediatr Infect Dis J 2004; 23 (Suppl 11): S193–S201.
   PubMedGoogle Scholar
• Rossi G, Medici M, Arcangeletti M, Lanari M, Merolla R, Paparatti UD et al. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007; 166 (12): 1267–1272.
   Google Scholar
• Smyth R, Openshaw P. Bronchiolitis. Lancet 2006; 368 (9532): 312-322.
   Google Scholar
• Meissner H, Welliver R, Chartrand S, Law B, Weisman L, Dorkin HL, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncy-tial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999; 18 (3): 223–231.
   PubMed Web of Science ®Google Scholar
• No authors listed. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 (3 Pt 1): 531-537.
   Google Scholar
• American Academy of Pediatrics. AAP guidelines for RSV immuno-prophylaxis. Redbook 2009.
   Google Scholar
• Pames C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003; 35 (6): 484-489.
   Google Scholar
• Klimek M, Kwinta P, Kruczek P, Pietrzyk JJ. Respiratory syncytial virus prophylaxis among preterm infants-four seasons' experience. Przegl Lek 2009; 66 (1-2): 34–38.
   PubMedGoogle Scholar
• Puddu M, Fanos V. Respiratory syncytial virus infection and recurrent wheezing: what next? J Chemother 2007; 19 (Suppl 2): 8–11.
   PubMedGoogle Scholar
• Corsello G. Bronchiolitis: the new American Academy of Pediatrics guidelines. J Chemother 2007; 19 (Suppl 2): 12–14.
   PubMedGoogle Scholar
• American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102 (2): 1211-1216.
   Google Scholar
• Canadian Paediatric Society (CPS) IDaIC. Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health 1999; 4 (7): 474-480.
   Google Scholar
• Forster J. Prophylaxis of RSV infections with immunoglobulins. Report of the German Society of Pediatric Infectiology (DGPI). Monatsschrift Kinder-heilkunde, 1999; 10: 971–972.
   Google Scholar
• Azar P, Broglia B, Miceli I, Parga L, Castillo E, et al. Guidelines for the use of palivizumab in the prevention of RSV disease: a consensus opinion. Pediatr Rev (Spanish), 2000; 21: 62–68.
   Google Scholar
• Marini A. Raccomandazioni per la prevenzione della malattia da virus respiratorio sinciziale (RSV). Riv Ital Pediatr, 2000; 26: 379–381.
   Google Scholar
• Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized con-trolled trials: a “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol. 2006; 41 (12): 1167–1174.
   PubMed Web of Science ®Google Scholar
• Wang E, Law B, Stephens D. Pediatric Investigators Collaborative Net-work on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower res-piratory tract infection. J Pediatr. 1995; 126 (2): 212–219.
   PubMed Web of Science ®Google Scholar
• Joffe S, Escobar G, Black S, Armstrong M, Lieu T. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics. 1999; 104(4 Pt 1): 894-899.
   Google Scholar
• Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Doménech E, Figueras-Aloy J. Rehospitalization because of respiratory syncytial virus in-fection in premature infants younger than 33 weeks of gestation: a prospec-tive study. IRIS Study Group. Pediatr Infect Dis J 2000; 19 (7): 592–597.
   PubMed Web of Science ®Google Scholar
• Hack M, DeMonterice D, Merkatz I, Jones P, Fanaroff A. Rehospital-ization of the very-low-birth-weight infant. A continuum of perinatal and en-vironmental morbidity. Am J Dis Child. 1981; 135 (3): 263–266.
   PubMedGoogle Scholar
• McCormick M, Shapiro S, Starfield B. Rehospitalization in the first year of life for high-risk survivors. Pediatrics 1980; 66 (6): 991–999.
   PubMedGoogle Scholar
• Imogen Morgan M. Late morbidity of very low birthweight infants. Br Med J (Clin Res Ed) 1985; 291 (6489): 171–173.
   PubMedGoogle Scholar
• The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pe-diatrics. 1997; 99 (1): 93-99.
   Google Scholar
• Sauve R, Singhal N. Long-term morbidity of infants with bronchopul-monary dysplasia. Pediatrics. 1985; 76 (5): 725–733.
   PubMed Web of Science ®Google Scholar
• Stevens T, Sinkin R, Hall C, Maniscako W, McConnochie K. Respi-ratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pe-diatr Adolesc Med. 2000; 154 (1): 55–61.
   PubMedGoogle Scholar
• Kusuda S, Koizumi T, Sakai T, Fujimura M, Nishida H, Togari H. Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003. Pediatr Int. 2006; 48 (4): 362–368.
   PubMed Web of Science ®Google Scholar
• Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitaliza-tions in premature infants. Pediatr Infect Dis J. 2003; 22 (9): 823–827.
   PubMed Web of Science ®Google Scholar
• Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon JB. Palivizumab efficacy in preterm infants with gestational age = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol. 2007; 42 (7): 189–192.
   PubMed Web of Science ®Google Scholar
• Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M, Palivizumab Outcomes Registry Group. Prevention of hospital-ization due to respiratory syncytial virus: results from the Palivizumab Out-comes Registry. J Perinatol 2008; 28 (7): 511–517.
   Google Scholar
• Fanos V, Scarcella A, Puddu M, Gallini F, Tuminelli F, Bragetti P, et al. Respiratory disorder and hospitalization rates during the second RSV sea-son in preterm infants who received palivizumab prophylaxis during their first RSV season. J Chemother 2009; 21 (3): 302–310.
   PubMed Web of Science ®Google Scholar